Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5267211
Max Phase: Preclinical
Molecular Formula: C32H31Br6N3O11
Molecular Weight: 1113.03
Associated Items:
ID: ALA5267211
Max Phase: Preclinical
Molecular Formula: C32H31Br6N3O11
Molecular Weight: 1113.03
Associated Items:
Canonical SMILES: COC1=C(Br)[C@@H](O)[C@]2(C=C1Br)CC(C(=O)NC[C@@H](O)COc1c(Br)cc(C(O)CNC(=O)C3=NO[C@@]4(C=C(Br)C(OC)=C(Br)[C@H]4O)C3)cc1Br)=CO2
Standard InChI: InChI=1S/C32H31Br6N3O11/c1-48-25-18(35)6-31(27(44)22(25)37)5-14(11-51-31)29(46)39-9-15(42)12-50-24-16(33)3-13(4-17(24)34)21(43)10-40-30(47)20-8-32(52-41-20)7-19(36)26(49-2)23(38)28(32)45/h3-4,6-7,11,15,21,27-28,42-45H,5,8-10,12H2,1-2H3,(H,39,46)(H,40,47)/t15-,21?,27-,28-,31-,32+/m1/s1
Standard InChI Key: GQWWFORCNIXEKH-SQYLNONJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1113.03 | Molecular Weight (Monoisotopic): 1106.7059 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Mishra SK, Tripathi G, Kishore N, Singh RK, Singh A, Tiwari VK.. (2017) Drug development against tuberculosis: Impact of alkaloids., 137 [PMID:28628823] [10.1016/j.ejmech.2017.06.005] |
Source(1):